Calidi Biotherapeutics
- 27/06/2023
- Series B
- $25,000,000
Calidi Biotherapeutics is a clinical-stage biopharmaceutical company revolutionizing oncolytic viral therapies with stem cell-based platforms.
- Industry Biotechnology Research
- Website https://www.calidibio.com/
- LinkedIn https://www.linkedin.com/company/calidibiotherapeutics/
Related People
Allan CamaisaFounder
Allan Camaisa is a serial entrepreneur, investor, and technologist, with proven leadership skills in bootstrapping startups. He has had four successful exits, which were sold to publicly traded Fortune 1000 companies. Mr. Camaisa has always created a tremendous return for his shareholders. He has proven operational experience in recruiting the right team as well as creating a culture of trust, and collaboration. Since taking over as Chairman and CEO of Calidi Biotherapeutics, he signed an agreement with National Institute of Health (NIH), recruited top immunologists to the Scientific Advisory Board, and entered license negotiations with large pharmaceutical organizations.
Previously, Mr. Camaisa was the CEO and Chairman of Parallel6, Inc., a creator of a digital mobile software platform that engaged clinical trial participants and powered the enrollment, management, and retention of those participants on behalf of pharmaceutical organizations. Parallel6 was sold to PRA Health Sciences in 2017. Their clients included Sanofi, STSI/Genentech, Johnson & Johnson/Janssen, Abbott/Abbvie, PPD, PRA Health, Pfizer, Roche, and the NIH, among others.
In 2005, Mr. Camaisa founded Anakam, Inc., a software security company, focused on healthcare, which safeguarded digital medical records through a platform that delivered government-level multifactor authentication and security. Anakam sold a global license to the Veterans Administration (VA) to secure access to the VA’s primary patient portal called My HealtheVet. Other notable Anakam clients included the Center for Medicare and Medicaid, the Department of Homeland Security and several medical device companies including Boston Scientific and EntraHealth. Anakam was recognized by INC 500 as one of the fastest growing companies in the U.S. and was acquired by Equifax in 2010.
Prior to Anakam, Mr. Camaisa founded High Technology Solutions (HTS), a software systems integrator that he grew from two people to more than 500 employees and $50 million in revenue. HTS was recognized as an INC 500 company three years in a row and was sold to Wireless Facilities, Inc. (now Kratos Defense) in 2004.
Before entering business, Mr. Camaisa served eight years as a surface warfare officer in the United States Navy. He currently owns seven U.S. patents and has received many personal awards including the Deloitte FAST 50, the Governor’s Small Business of the Year Award and the Ernst and Young Regional Entrepreneur of the Year. He also received awards from the San Diego Asian Business Association and many other awards.